tiprankstipranks
Trending News
More News >
Pfizer Inc (PFE)
:PFE
US Market
Advertisement

Pfizer (PFE) Earnings Dates, Call Summary & Reports

Compare
35,447 Followers

Earnings Data

Report Date
Feb 03, 2026
Before Open (Confirmed)
Period Ending
2025 (Q4)
Consensus EPS Forecast
0.66
Last Year’s EPS
0.63
Same Quarter Last Year
Based on 14 Analysts Ratings

Earnings Call Summary

Q3 2025
Earnings Call Date:Nov 04, 2025|
% Change Since:
|
Earnings Call Sentiment|Neutral
Pfizer's earnings call was mixed, highlighting strategic advancements and financial performance, but also facing challenges in COVID-19 product revenue declines and ongoing legal issues with the Metsera acquisition.
Company Guidance
During Pfizer's Third Quarter 2025 Earnings Conference Call, the company provided guidance reflecting strong performance and strategic initiatives. Pfizer reported revenues of $16.7 billion for the quarter, with a 7% operational decrease compared to the same period last year, largely driven by a decline in COVID-19 products. Despite this, non-COVID products grew 4% operationally. Adjusted diluted earnings per share were $0.87, exceeding expectations due to gross margin and cost management performance. Pfizer raised the full-year 2025 adjusted diluted EPS guidance to a range of $3.00 to $3.15. Key strategic moves included the proposed acquisition of Metsera and a licensing agreement with 3SBio, which are expected to be dilutive to 2026 EPS but promising for long-term growth. Pfizer highlighted continued strong demand for key products like the Vyndaqel family, achieving 7% year-over-year growth, and Nurtec with 22% global operational growth. The company also emphasized ongoing R&D advancements, such as the promising results from the PHAROS trial for Braftovi and Mektovi, and the progress in their pneumococcal vaccine programs. The call underscored Pfizer's commitment to maintaining leadership in their markets while navigating a complex external environment, including a recent agreement with the U.S. government impacting future pricing strategies.
Strategic Agreement with U.S. Government
Pfizer reached a landmark agreement with the U.S. government, providing clarity on future innovation and growth. The agreement includes a 3-year grace period from certain U.S. tariffs and aims to lower prescription drug costs.
Proposed Acquisition of Metsera
Pfizer is pursuing the acquisition of Metsera, which they believe will create substantial value for shareholders and advance innovation in obesity treatments.
R&D Pipeline and Innovations
Pfizer's R&D pipeline is growing with advancements in cancer immunotherapy, lung cancer treatments, and prostate cancer therapies. Notable Phase III data showed significant benefits for patients in various trials.
Strong Financial Performance and EPS Guidance
Pfizer raised its adjusted diluted EPS guidance for 2025 due to strong gross margin and cost management performance, despite lower COVID-19 product revenues.

Pfizer (PFE) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

PFE Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Feb 03, 2026
2025 (Q4)
0.66 / -
0.63
Nov 04, 2025
2025 (Q3)
0.63 / 0.87
1.06-17.92% (-0.19)
Aug 06, 2025
2025 (Q2)
0.58 / 0.78
0.630.00% (+0.18)
Apr 29, 2025
2025 (Q1)
0.67 / 0.92
0.8212.20% (+0.10)
Feb 04, 2025
2024 (Q4)
0.47 / 0.63
0.1530.00% (+0.53)
Oct 29, 2024
2024 (Q3)
0.61 / 1.06
-0.17723.53% (+1.23)
Jul 30, 2024
2024 (Q2)
0.46 / 0.60
0.67-10.45% (-0.07)
May 01, 2024
2024 (Q1)
0.52 / 0.82
1.23-33.33% (-0.41)
Jan 30, 2024
2023 (Q4)
-0.16 / 0.10
1.14-91.23% (-1.04)
Oct 31, 2023
2023 (Q3)
-0.08 / -0.17
1.78-109.55% (-1.95)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

PFE Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 04, 2025
$24.66$24.30-1.46%
Aug 06, 2025
$24.75$23.93-3.31%
Apr 29, 2025
$22.23$22.95+3.24%
Feb 04, 2025
$25.27$24.96-1.23%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Pfizer Inc (PFE) report earnings?
Pfizer Inc (PFE) is schdueled to report earning on Feb 03, 2026, Before Open (Confirmed).
    What is Pfizer Inc (PFE) earnings time?
    Pfizer Inc (PFE) earnings time is at Feb 03, 2026, Before Open (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is PFE EPS forecast?
          PFE EPS forecast for the fiscal quarter 2025 (Q4) is 0.66.

            Pfizer (PFE) Earnings News

            PFE Earnings: Pfizer Stock Slips as EPS & Revenue Fall
            Premium
            Market News
            PFE Earnings: Pfizer Stock Slips as EPS & Revenue Fall
            3d ago
            PFE Earnings: Pfizer Stock Climbs on Strong Q2 and Upbeat Guidance
            Premium
            Market News
            PFE Earnings: Pfizer Stock Climbs on Strong Q2 and Upbeat Guidance
            3M ago
            MRNA Earnings: Moderna Stock Slumps 10% on Lower Covid Vaccine Demand
            Premium
            Market News
            MRNA Earnings: Moderna Stock Slumps 10% on Lower Covid Vaccine Demand
            3M ago
            PFE Earnings: Pfizer Stock Jumps on Q4 Beats
            Premium
            Market News
            PFE Earnings: Pfizer Stock Jumps on Q4 Beats
            9M ago
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis